Joan Dabu, MD
Pulmonary Disease · Rancho Mirage, CANPI 1891192696
Payments from drug & device makers
Across 21 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galvanize Therapeutics, Inc$136
- AstraZeneca$82
- GSK$75
- Sanofi$68
- Medtronic$35
- Insmed, Inc.$30
- plus $128 from 6 others
What the payments were for
- Food & beverage$554100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galvanize Therapeutics, Inc | 1 | $136 |
| AstraZeneca | 4 | $82 |
| GSK | 4 | $75 |
| Sanofi | 3 | $68 |
| Medtronic | 1 | $35 |
| Insmed, Inc. | 1 | $30 |
| Electromed, Inc. | 2 | $30 |
| Grifols USA, LLC | 1 | $23 |
| Baxter Healthcare | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Philips North America LLC | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$136
How this compares
$554 in reported general payments places this provider in the 35th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 217 | $184,445 |
| Breo ElliptaFluticasone/Vilanterol | 323 | $161,495 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 126 | $75,703 |
| Incruse ElliptaUmeclidinium Bromide | 153 | $72,055 |
| Dupixent SyringeDupilumab | 15 | $56,004 |
| Spiriva RespimatTiotropium Bromide | 69 | $49,288 |
| Spiriva HandihalerTiotropium Bromide | 47 | $32,320 |
| EliquisApixaban | 28 | $26,577 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $21,389 |
| Tiotropium Bromide | 25 | $16,099 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 110 | $15,484 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,753 |
| Advair DiskusFluticasone Propion/Salmeterol | 46 | $13,470 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $13,333 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 450 | $13,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $75 | $501,772852 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $21 | $70,677108 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $82 | $24,55460 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Rancho Mirage
- Justin ThomasRancho Mirage$439K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.